MA43619B1 - Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci - Google Patents

Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci

Info

Publication number
MA43619B1
MA43619B1 MA43619A MA43619A MA43619B1 MA 43619 B1 MA43619 B1 MA 43619B1 MA 43619 A MA43619 A MA 43619A MA 43619 A MA43619 A MA 43619A MA 43619 B1 MA43619 B1 MA 43619B1
Authority
MA
Morocco
Prior art keywords
isoquinolin
carboxamides
preparation
isoquinoline
disorders
Prior art date
Application number
MA43619A
Other languages
English (en)
Other versions
MA43619A1 (fr
Inventor
Sunil Kumar Kc
Gopi Kumar Mittapalli
Chi Ching Mak
Venkataiah Bollu
Chandramouli Chiruta
Jianguo Cao
Brian Eastman
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of MA43619A1 publication Critical patent/MA43619A1/fr
Publication of MA43619B1 publication Critical patent/MA43619B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés isoquinoline destinés à traiter diverses maladies et pathologies. Plus particulièrement, la présente invention concerne l'utilisation d'un composé isoquinoline, ou d'analogues de celui-ci, dans le traitement de troubles caractérisés par l'activation de la signalisation de la voie wnt (par exemple un cancer, une prolifération cellulaire anormale, une angiogenèse, des troubles fibrotiques, des maladies osseuses ou cartilagineuses, et une ostéoarthrite), la modulation d'évén
MA43619A 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci MA43619B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328255P 2016-04-27 2016-04-27
PCT/US2017/029805 WO2017189829A1 (fr) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci

Publications (2)

Publication Number Publication Date
MA43619A1 MA43619A1 (fr) 2019-10-31
MA43619B1 true MA43619B1 (fr) 2020-10-28

Family

ID=60157337

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43619A MA43619B1 (fr) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci

Country Status (28)

Country Link
US (7) US10106527B2 (fr)
EP (2) EP3892276A1 (fr)
JP (1) JP6993985B2 (fr)
KR (1) KR102374844B1 (fr)
CN (1) CN109310690B (fr)
AR (1) AR108325A1 (fr)
AU (1) AU2017258193B2 (fr)
CA (1) CA3022002A1 (fr)
CL (2) CL2018003065A1 (fr)
CO (1) CO2018012299A2 (fr)
CY (1) CY1124302T1 (fr)
DK (1) DK3448386T3 (fr)
ES (1) ES2865374T3 (fr)
HR (1) HRP20210607T1 (fr)
HU (1) HUE054103T2 (fr)
IL (1) IL262470B (fr)
LT (1) LT3448386T (fr)
MA (1) MA43619B1 (fr)
MD (1) MD3448386T2 (fr)
MX (1) MX2018013174A (fr)
PE (1) PE20190326A1 (fr)
PH (1) PH12018502258A1 (fr)
PL (1) PL3448386T3 (fr)
PT (1) PT3448386T (fr)
RS (1) RS61879B1 (fr)
SG (2) SG10201914054SA (fr)
SI (1) SI3448386T1 (fr)
WO (1) WO2017189829A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2017079759A1 (fr) 2015-11-06 2017-05-11 Samumed, Llc 2-(3h-indazol-3-yl)-1h-imidazo[4,5-c]pyridines et leurs utilisations anti-inflammatoires
ES2879995T3 (es) 2015-12-10 2021-11-23 Ptc Therapeutics Inc Métodos para el tratamiento de la enfermedad de Huntington
AR108325A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
MX2018014871A (es) 2016-06-01 2019-11-05 Samumed Llc Proceso de preparacion de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4, 5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida .
PE20200008A1 (es) 2017-03-30 2020-01-06 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1
WO2018226622A1 (fr) 2017-06-05 2018-12-13 Ptc Therapeutics, Inc. Composés permettant de traiter la maladie de huntington
CA3067592A1 (fr) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methodes de traitement de la maladie de huntington
EP3644996B1 (fr) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Procédés de traitement de la maladie de huntington
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
WO2019084497A1 (fr) 2017-10-27 2019-05-02 Samumed, Llc 6-(hétéroaryle et aryle à 6 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
WO2019084496A1 (fr) 2017-10-27 2019-05-02 Samumed, Llc 6-(hétéroaryle à 5 chaînons)isoquinolin-3-yl-(hétéroaryle à 5 chaînons)carboxamides, leur préparation et leur utilisation
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
CN112292183A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑
EP3807261B1 (fr) 2018-06-18 2022-07-13 Janssen Pharmaceutica NV Pyridinyl-pyrazoles utilisés utilisés comme modulateurs de roryt
WO2019244000A1 (fr) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Imidazoles substitués par phényle et pyridinyle utilisés en tant que modulateurs de roryt
WO2019243999A1 (fr) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyrazoles substitués par phényle utilisés en tant que modulateurs de roryt
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
WO2020005873A1 (fr) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Composés hétérocycliques et hétéroaryles pour le traitement de la maladie de huntington
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2020150552A2 (fr) 2019-01-17 2020-07-23 Samumed, Llc Procédés de traitement de troubles du cartilage par inhibition de clk et dyrk
WO2021007378A1 (fr) * 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Composés destinés à être utilisés dans le traitement de la maladie de huntington
WO2021004547A1 (fr) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Composés hétérocycliques utilisés en tant qu'inhibiteurs de hpk1
US20230193265A1 (en) * 2020-05-20 2023-06-22 Osaka University Cug repeat sequence binding agent
CN117088876A (zh) * 2020-10-28 2023-11-21 杭州阿诺生物医药科技有限公司 一种高活性Wnt通路抑制剂化合物
TW202321244A (zh) * 2021-07-26 2023-06-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Ｗｎｔ通路抑制劑化合物
TW202334157A (zh) * 2022-01-29 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Ｗｎｔ通路抑制劑化合物
WO2024022365A1 (fr) * 2022-07-28 2024-02-01 杭州阿诺生物医药科技有限公司 Composé inhibiteur de la voie wnt

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
JP4681548B2 (ja) 2003-07-22 2011-05-11 アステックス・セラピューティクス・リミテッド ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20060264897A1 (en) 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2007125405A2 (fr) 2006-05-01 2007-11-08 Pfizer Products Inc. Composés hétérocycliques 2-amino-substitués à cycles fusionnés
EP2195328A4 (fr) 2007-08-15 2011-06-15 Cytokinetics Inc Entités chimiques particulières, compositions, et procédés
WO2009085226A2 (fr) 2007-12-21 2009-07-09 Sirtris Pharmaceuticals, Inc. Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CN102595900B (zh) 2009-08-10 2015-07-15 萨穆梅德有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
CN102595899A (zh) 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
US7998878B2 (en) 2009-11-20 2011-08-16 Eastman Kodak Company Method for selective deposition and devices
ES2550820T3 (es) 2009-12-21 2015-11-12 Samumed, Llc 1H-pirazol[3,4-beta]piridinas y usos terapéuticos de las mismas
BR112012024705A2 (pt) 2010-03-31 2016-06-07 Actelion Pharmaceuticals Ltd derivados antibacterianos de isoquinolin-3-ilureia
AR084280A1 (es) * 2010-12-17 2013-05-02 Hoffmann La Roche Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos
CN102558173B (zh) * 2010-12-31 2015-05-20 广州源生医药科技有限公司 抑制wnt信号传导的化合物、组合物及其应用
EP2755483B1 (fr) 2011-09-14 2018-11-28 Samumed, LLC Indazole-3-carboxamides et leur utilisation en tant qu'inhibiteurs de la voie de signalisation par wnt/ -caténine
WO2013169793A2 (fr) * 2012-05-09 2013-11-14 Ipierian, Inc. Procédés et compositions pour des protéinopathies tdp-43
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
EP3119393A4 (fr) 2014-03-20 2018-02-28 Samumed, LLC Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
US10722515B2 (en) 2016-09-30 2020-07-28 Sri International Dual CLK/CDK1 inhibitors for cancer treatment
WO2020006115A1 (fr) 2018-06-26 2020-01-02 Betty Tam Méthodes de traitement du cancer à l'aide d'un inhibiteur de clk
WO2020150545A1 (fr) 2019-01-17 2020-07-23 Samumed, Llc DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE

Also Published As

Publication number Publication date
CA3022002A1 (fr) 2017-11-02
CN109310690B (zh) 2021-09-07
US20220332698A1 (en) 2022-10-20
HUE054103T2 (hu) 2021-08-30
PE20190326A1 (es) 2019-03-05
US11548872B2 (en) 2023-01-10
CY1124302T1 (el) 2022-07-22
US10100038B2 (en) 2018-10-16
CL2019001343A1 (es) 2019-10-11
IL262470A (en) 2018-12-31
US20190233396A1 (en) 2019-08-01
MX2018013174A (es) 2019-02-13
US10947217B2 (en) 2021-03-16
CL2018003065A1 (es) 2019-02-01
DK3448386T3 (da) 2021-04-26
JP6993985B2 (ja) 2022-01-14
CN109310690A (zh) 2019-02-05
AU2017258193B2 (en) 2021-06-03
US9951048B1 (en) 2018-04-24
RU2018141395A (ru) 2020-05-28
AR108325A1 (es) 2018-08-08
CO2018012299A2 (es) 2019-04-30
US20180155323A1 (en) 2018-06-07
BR112018072169A8 (pt) 2022-11-08
MA43619A1 (fr) 2019-10-31
AU2017258193A1 (en) 2018-11-15
IL262470B (en) 2021-12-01
EP3448386B1 (fr) 2021-03-03
MD3448386T2 (ro) 2022-05-31
LT3448386T (lt) 2021-06-25
HRP20210607T1 (hr) 2021-06-25
PT3448386T (pt) 2021-04-22
US20170313682A1 (en) 2017-11-02
EP3448386A4 (fr) 2019-12-18
BR112018072169A2 (pt) 2019-02-12
US20230286945A1 (en) 2023-09-14
SG11201809301YA (en) 2018-11-29
RU2018141395A3 (fr) 2020-08-13
SG10201914054SA (en) 2020-03-30
JP2019514938A (ja) 2019-06-06
WO2017189829A1 (fr) 2017-11-02
EP3892276A1 (fr) 2021-10-13
EP3448386A1 (fr) 2019-03-06
SI3448386T1 (sl) 2021-08-31
US10106527B2 (en) 2018-10-23
KR102374844B1 (ko) 2022-03-16
US20200299263A1 (en) 2020-09-24
KR20190014505A (ko) 2019-02-12
RS61879B1 (sr) 2021-06-30
US10544128B2 (en) 2020-01-28
US20180093970A1 (en) 2018-04-05
PL3448386T3 (pl) 2021-11-02
ES2865374T3 (es) 2021-10-15
PH12018502258A1 (en) 2019-09-16

Similar Documents

Publication Publication Date Title
MA43619B1 (fr) Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci
MA43605A1 (fr) Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci
MA37450A1 (fr) Inhibiteurs d'indazole du trajet de signal de wnt et leurs utilisations thérapeutiques
MA46018A (fr) Activateurs d'édition du génome
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
TN2009000551A1 (fr) Nouveaux composes chimiques
MA44549A1 (fr) Agents immunorègulateurs
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA31156B1 (fr) Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os
MXPA03011083A (es) Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii.
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
MA31022B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
MA38284A1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA32506B1 (fr) Nouveaux composes
ATE461697T1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
MA38425B1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA49947B1 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MA45639B1 (fr) Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase
FR3088542B1 (fr) Composition cicatrisante comprenant une eau électrolysée
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
MA31385B1 (fr) Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives